Literature DB >> 24102876

Invasive Aspergillus niger complex infections in a Belgian tertiary care hospital.

E Vermeulen1, J Maertens, P Meersseman, V Saegeman, L Dupont, K Lagrou.   

Abstract

The incidence of invasive infections caused by the Aspergillus niger species complex was 0.043 cases/10 000 patient-days in a Belgian university hospital (2005-2011). Molecular typing was performed on six available A. niger complex isolates involved in invasive disease from 2010 to 2011, revealing A. tubingensis, which has higher triazole minimal inhibitory concentrations, in five out of six cases.
© 2013 The Authors Clinical Microbiology and Infection © 2013 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Keywords:  Aspergillosis; Aspergillus niger; Aspergillus niger infection; Invasive pulmonary aspergillosis; drug resistance; fungal

Mesh：

Substances：

Year:  2013        PMID： 24102876     DOI： 10.1111/1469-0691.12394

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


  12 in total

1.  Species Distribution and In Vitro Azole Susceptibility of Aspergillus Section Nigri Isolates from Clinical and Environmental Settings.

Authors:  Roberta Iatta; Federica Nuccio; Davide Immediato; Adriana Mosca; Carmela De Carlo; Giuseppe Miragliotta; Antonio Parisi; Giuseppe Crescenzo; Domenico Otranto; Claudia Cafarchia
Journal:  J Clin Microbiol       Date:  2016-07-13       Impact factor: 5.948

2.  Species Distribution and Comparison between EUCAST and Gradient Concentration Strips Methods for Antifungal Susceptibility Testing of 112 Aspergillus Section Nigri Isolates.

Authors:  B Carrara; R Richards; S Imbert; F Morio; M Sasso; N Zahr; A C Normand; P Le Pape; L Lachaud; S Ranque; D Maubon; R Piarroux; A Fekkar
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

3.  Identification and susceptibility of Aspergillus section nigri in china: prevalence of species and paradoxical growth in response to echinocandins.

Authors:  Yali Li; Zhe Wan; Wei Liu; Ruoyu Li
Journal:  J Clin Microbiol       Date:  2014-12-10       Impact factor: 5.948

4.  New Insights into the Cyp51 Contribution to Azole Resistance in Aspergillus Section Nigri.

Authors:  Alba Pérez-Cantero; Loida López-Fernández; Josep Guarro; Javier Capilla
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

5.  Aspergillus niger bloodstream infection in gastric cancer after common hepatic artery embolization: A case report.

Authors:  Li Lin; Chuan-Hua Zhao; Xiu-Yun Yin; Yu-Ling Chen; Hong-Yan Zhai; Chun-Wei Xu; Yan Wang; Fei-Jiao Ge; Jian-Ming Xu
Journal:  Exp Ther Med       Date:  2017-06-27       Impact factor: 2.447

6.  Aspergillus nodules in chronic granulomatous disease attributable to Aspergillus ochraceus.

Authors:  Samihah Moazam; David W Denning
Journal:  Med Mycol Case Rep       Date:  2017-06-21

7.  Microbiological and immunological characteristics of a lethal pulmonary Aspergillus niger infection in a non-neutropenic patient.

Authors:  Jessica D Workum; Suzanne W de Jong; Mark S Gresnigt; Katharina L Becker; Peter Pickkers; Frank L van de Veerdonk; Yvonne F Heijdra; Eva Kolwijck
Journal:  Med Mycol Case Rep       Date:  2018-03-07

8.  Phylogenetic Identification, Diversity, and Richness of Aspergillus from Homes in Havana, Cuba.

Authors:  Kenia C Sánchez Espinosa; Michel Almaguer Chávez; Esperanza Duarte-Escalante; Teresa Irene Rojas Flores; María Guadalupe Frías-De-León; María Del Rocío Reyes-Montes
Journal:  Microorganisms       Date:  2021-01-06

Review 9.  New insights on the development of fungal vaccines: from immunity to recent challenges.

Authors:  Natasha P Medici; Maurizio Del Poeta
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-11-24       Impact factor: 2.743

10.  The potency of luliconazole against clinical and environmental Aspergillus nigri complex.

Authors:  Sahar Hivary; Mahnaz Fatahinia; Marzieh Halvaeezadeh; Ali Zarei Mahmoudabadi
Journal:  Iran J Microbiol       Date:  2019-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.